Skip to content

to Study the Role of Retrograde Intrarenal Surgery in Management of Renal Stones

Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05648877
Enrollment
77
Registered
2022-12-13
Start date
2020-10-01
Completion date
2023-04-01
Last updated
2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retrograde Intrarenal Surgery In Management Of Renal Stones

Keywords

Renal pelvic stone, Semi-rigid URS, Flexible URS, Treatment

Brief summary

Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience

Detailed description

With the advancements in endourologic technology, in the last 30 years, renal stone treatment has dramatically changed, and minimally invasive treatments options, such as extracorporeal shock wave lithotripsy (SWL), percutaneous nephrolithotomy (PCNL), mini-PCNL, retrograde intrarenal surgery (RIRS) or laparoscopy, have replaced open surgery. Although, minimally invasive treatment modalities have an excellent stone fragmentation rate, the clearance of stone fragments may not be immediate and can occur for any time after the intervention. The European Association of Urology (EAU) guidelines, recommends PCNL for renal stones greater than 2 cm, and SWL is suggested primarily for stones less than 1 cm in size. Although SWL, RIRS and PCNL are all presented as treatment options for renal stones between, which application is a matter of preference. The treatment modality selection of renal stones usually depends on stone-related factors (location, size, and composition), clinical factors (patient's comorbidities, patient's compliance, solitary kidney, and abnormal anatomy), and technical factors (equipment available for treatment, success rates, possible complications, invasiveness, the need for anesthetics, hospitalization times, and costs). PCNL can achieve better results but is more invasive, is associated with greater morbidity and complications, and may be reserved for selected circumstances. Stone clearance following kidney stone treatment is not well defined. For lower pole stones, Sener and colleagues compared RIRS with SWL and reported a stone-free rate of 52.3% with patients treated using RIRS one week after treatment. However after three months, the stone-free rate improved to 100%. Ureteroscopic lithotripsy has been the most widely applied treatment for urinary tract stones, with high success and low complication rates. The holmium laser has facilitated the disintegration of stones and increased the effectiveness of ureteroscopic lithotripsy. Improvements in the new generation of flexible ureteroscopes have made retrograde endoscopic ureteroscopy and laser lithotripsy for renal calculi more popular. The overall success rates of retrograde intrarenal surgery have been reported as 75% to 95% for intrarenal stones \> 2 cm after the first or second treatment, whereas the major and minor complication rates vary from 1.5% to 12%, which are less frequent than rates in PCNL procedures.

Interventions

DEVICEUreteroscope

Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience

Sponsors

Menoufia University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients with renal stones were eligible for the procedure. Patients with difficult PCNL

Exclusion criteria

* Uncorrected coagulopathy Distal obstruction Active urinary tract infection Ureteropelvic junction obstruction Congenital renal anomalies Staghorn stones

Design outcomes

Primary

MeasureTime frameDescription
stone free rates and complicationsUp to 6 monthsStone free rates of both semirigid and flexible URS

Countries

Egypt

Contacts

Primary ContactMohammed A Abdelghaffar, Bachelor
mohammed20207501@gmail.com01555950089

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026